Precision BioSciences Announces Allowance of Five Additional U.S. Patent Applications Related to Engineered Meganucleases
2/23/2012 6:13:21 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued Notices of Allowance for five U.S. Patent Applications: 12/879,428, 13/246,263, 13/245,650, 13/246,355 and 13/246,376 (“the Applications”). The allowed claims relate to a broad set of genome engineering methods and materials. These methods constitute multiple aspects of Precision’s genome engineering technology known as the Directed Nuclease Editor or DNE.
comments powered by